Advertisement
REGN vs SMMT
Which Stock Would AI Choose? Regeneron Pharmaceuticals (REGN) vs. Summit Therapeutics (SMMT) Stock Comparison
Key Takeaways
- Regeneron Pharmaceuticals (REGN) maintains stability as a large-cap biotech leader with a market capitalization over $79 billion and trailing twelve-month (TTM) revenue of $14.34 billion.
- Summit Therapeutics (SMMT) has surged approximately 38% in recent market activity, fueled by positive Phase III data and U.S. Food and Drug Administration (FDA) Biologics License Application (BLA) acceptance for ivonescimab.
- REGN is profitable with a price-to-earnings (P/E) ratio of 18.23, while SMMT remains pre-revenue and loss-making.
- Recent sentiment favors SMMT due to oncology pipeline catalysts, contrasting REGN's steady performance ahead of quarterly earnings.
- REGN exhibits lower volatility with a beta of 0.40 (a measure of stock price sensitivity to market movements), compared to SMMT's beta of -1.37.
- Over the past year, REGN delivered stronger gains of about 26%, outperforming SMMT's more volatile trajectory.
Introduction
This stock comparison pits Regeneron Pharmaceuticals (REGN), a mature biotech giant with blockbuster drugs, against Summit Therapeutics (SMMT), an emerging player banking on oncology breakthroughs. Investors seeking balanced portfolios may weigh REGN's proven revenue stability against SMMT's high-upside potential from clinical milestones. Traders focused on relative performance and market positioning will find value in analyzing their contrasting momentum, risk profiles, and sector dynamics in the current biotech landscape.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) is a leading biopharmaceutical company specializing in treatments for eye diseases, cancer, allergic and inflammatory conditions, and more, with key products like Eylea and Dupixent collaborations driving revenue. In recent weeks, the stock has traded steadily around the mid-$700s, reflecting resilience amid broader market fluctuations. Influences include anticipation for first-quarter earnings, a new free in vivo gene therapy launch, and a U.S. government pricing agreement that has supported sentiment. Year-to-date gains hover near 2%, with low-beta stability underscoring its defensive positioning in biotech.
SMMT Overview and Recent Performance
Summit Therapeutics (SMMT) focuses on oncology, particularly its lead candidate ivonescimab, a PD-1/VEGF bispecific antibody targeting non-small cell lung cancer (NSCLC). Recent market activity has been volatile yet upward-trending, with shares climbing about 38% over the past month following Phase III trial successes and FDA BLA filing acceptance. The stock has consolidated after peaks near $37, supported by multiple data presentations at conferences like ELCC 2026. Year-to-date performance exceeds 26%, though high volatility reflects clinical-stage risks and binary outcomes.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights 25 top bots curated from 351 AI Trading Bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots earn their spot through superior adaptation to current market volatility, boasting annualized returns from +15% to +167%, win rates of 48% to 88%, profit factors up to 11.70, and strategies spanning 5-minute scalps to multi-day holds on 1 to 25 tickers. Themes include semiconductors, gold miners, small caps, and leveraged ETFs. Traders benefit from real-time copy-trading signals with risk controls. Visit the page to discover bots matching your style amid today’s conditions.
Head-to-Head Comparison
Regeneron Pharmaceuticals (REGN) and Summit Therapeutics (SMMT) both anchor in biotechnology but diverge sharply in business models: REGN leverages diversified commercial revenues from approved therapies, while SMMT centers on a single late-stage asset, ivonescimab. Growth drivers contrast REGN's steady TTM revenue expansion with SMMT's potential blockbuster approval. Recent momentum favors SMMT's surge on trial data versus REGN's flat trajectory. Risk factors amplify for SMMT via regulatory hurdles and negative beta, while REGN offers sector resilience. Market sentiment tilts toward SMMT's catalysts despite REGN's scale advantage.
Tickeron AI Verdict
Tickeron’s AI currently favors Summit Therapeutics (SMMT) for its trend consistency in recent weeks, bolstered by clinical catalysts and relative outperformance, positioning it ahead probabilistically in the short term. Regeneron Pharmaceuticals (REGN) appeals for long-term stability and profitability, though lacking near-term momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Hold and SMMT is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 2 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).
- REGN’s FA Score: 2 green, 3 red.
- SMMT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 3 TA indicator(s) are bullish while SMMT’s TA Score has 5 bullish TA indicator(s).
- REGN’s TA Score: 3 bullish, 5 bearish.
- SMMT’s TA Score: 5 bullish, 4 bearish.
Price Growth
REGN (@Biotechnology) experienced а +1.92% price change this week, while SMMT (@Biotechnology) price change was +12.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.57%. For the same industry, the average monthly price growth was +5.22%, and the average quarterly price growth was +13.90%.
Reported Earning Dates
REGN is expected to report earnings on Jul 30, 2026.
SMMT is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (+1.57% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| REGN | SMMT | REGN / SMMT | |
| Capitalization | 74.9B | 14B | 535% |
| EBITDA | 5.75B | -1.21B | -476% |
| Gain YTD | -7.271 | 3.373 | -216% |
| P/E Ratio | 17.45 | 26.36 | 66% |
| Revenue | 14.9B | 0 | - |
| Total Cash | 8.75B | 599M | 1,461% |
| Total Debt | 2.71B | 20M | 13,530% |
REGN | SMMT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 77 | 67 | |
SMR RATING 1..100 | 58 | 100 | |
PRICE GROWTH RATING 1..100 | 57 | 57 | |
P/E GROWTH RATING 1..100 | 30 | 9 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (4) in the Biotechnology industry is significantly better than the same rating for SMMT (92). This means that REGN’s stock grew significantly faster than SMMT’s over the last 12 months.
SMMT's Profit vs Risk Rating (67) in the Biotechnology industry is in the same range as REGN (77). This means that SMMT’s stock grew similarly to REGN’s over the last 12 months.
REGN's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for SMMT (100). This means that REGN’s stock grew somewhat faster than SMMT’s over the last 12 months.
REGN's Price Growth Rating (57) in the Biotechnology industry is in the same range as SMMT (57). This means that REGN’s stock grew similarly to SMMT’s over the last 12 months.
SMMT's P/E Growth Rating (9) in the Biotechnology industry is in the same range as REGN (30). This means that SMMT’s stock grew similarly to REGN’s over the last 12 months.
| REGN | SMMT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 76% | 4 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 71% | 4 days ago 78% |
| Momentum ODDS (%) | 4 days ago 58% | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 49% | 4 days ago 85% |
| TrendWeek ODDS (%) | 4 days ago 65% | 4 days ago 86% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 85% |
| Advances ODDS (%) | N/A | 6 days ago 85% |
| Declines ODDS (%) | 13 days ago 52% | 13 days ago 82% |
| BollingerBands ODDS (%) | 4 days ago 60% | 4 days ago 84% |
| Aroon ODDS (%) | 4 days ago 63% | 4 days ago 89% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GDXU | 203.99 | 16.33 | +8.70% |
| MicroSectors™ Gold Miners 3X Lvrgd ETN | |||
| MST | 36.14 | 1.85 | +5.38% |
| Defiance Leveraged Long + Inc MSTR ETF | |||
| UTEN | 43.47 | 0.12 | +0.27% |
| F/m US Treasury 10 Year Note ETF | |||
| ROPE | 28.58 | -0.07 | -0.25% |
| Coastal Compass 100 ETF | |||
| TWM | 23.58 | -0.33 | -1.38% |
| ProShares UltraShort Russell2000 | |||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +0.82% | ||
| SMMT - REGN | 43% Loosely correlated | +5.42% | ||
| ARQT - REGN | 39% Loosely correlated | +2.47% | ||
| IDYA - REGN | 35% Loosely correlated | +0.28% | ||
| GMAB - REGN | 34% Loosely correlated | -2.33% | ||
| INCY - REGN | 33% Poorly correlated | +0.81% | ||
More | ||||
SMMT and
Correlation & Price change
A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.
| Ticker / NAME | Correlation To SMMT | 1D Price Change % | ||
|---|---|---|---|---|
| SMMT | 100% | +5.42% | ||
| BCDA - SMMT | 70% Closely correlated | +1.83% | ||
| IDYA - SMMT | 44% Loosely correlated | +0.28% | ||
| REGN - SMMT | 43% Loosely correlated | +0.82% | ||
| VBIZF - SMMT | 42% Loosely correlated | -40.97% | ||
| CRBU - SMMT | 40% Loosely correlated | +3.19% | ||
More | ||||